Profound Medical Corp (PROF) FinancialsPROFFinancialProfound Medical Corp

Profound Medical Corp (PROF) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Contracts with Customers, accounting for 89.3% of total sales, equivalent to $2.34M. Another important revenue stream is Leasing. Understanding this composition is critical for investors evaluating how PROF navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Profound Medical Corp maintains a gross margin of 78.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -445.67%, while the net margin is -384.21%. These profitability ratios, combined with a Return on Equity (ROE) of -73.53%, provide a clear picture of how effectively PROF converts its operational activities into shareholder value.

In the context of the broader market, PROF competes directly with industry leaders such as YDES and CATX. With a market capitalization of $250.25M, it holds a significant position in the sector. When comparing efficiency, PROF's gross margin of 78.41% stands against YDES's 28.05% and CATX's 100.00%. Such benchmarking helps identify whether Profound Medical Corp is trading at a premium or discount relative to its financial performance.

Profound Medical has shown significant revenue growth, with Q1 2026 revenue at $5.3 million, a 104% increase year-over-year, but has struggled with profitability, reporting a net income loss of -$9.54 million in Q2 2026.